Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 48 Hours
The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 3.3% during the forecast period. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.
Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma’s cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer stem cell inhibitor targeting STAT-3.
There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.
Upcoming patent expiries of key products such as Roche’s Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.
Further key findings from the report suggest:
The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 3.3% during the forecast period. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.
Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma’s cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon’s Napabucasin is a cancer stem cell inhibitor targeting STAT-3.
There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.
Upcoming patent expiries of key products such as Roche’s Avastin, Amgen’s Vectibix, and Sanofi’s Zaltrap will lead to biosimilar penetration. Amgen/Allergan’s Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.
Further key findings from the report suggest:
- Immunotherapy dominated the market based on drug class in 2016, owing to increasing adoption of targeted therapies such as Avastin and Erbitux
- Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action
- U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs
- Roche led the colorectal cancer industrial setting in 2016 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2016. However, Roche is projected to lose market share on grounds of Avastin’s patent expiry and biosimilar penetration
- Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Stages:
3.1.2 Symptoms
3.1.3 Risk Factors
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL COLORECTAL CANCER DRUGS MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Segmentation, by Drug Class
4.1.1.1 Chemotherapy
4.1.1.1.1 Antimetabolites
4.1.1.1.2 Alkylating agents
4.1.1.2 Immunotherapy
4.1.1.2.1 Biologic Response Modifiers
4.1.1.2.2 Colony-Stimulating Factors
4.1.1.2.3 Tumor Vaccines
4.1.1.2.4 Monoclonal Antibodies
4.1.2 Segmentation, by Region
4.1.2.1 U.S.
4.1.2.2 U.K.
4.1.2.3 Germany
4.1.2.4 Spain
4.1.2.5 Italy
4.1.2.6 France
4.1.2.7 Japan
4.1.3 Market size and forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (YTD 2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 SWOT Analysis
CHAPTER 5 COLORECTAL CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Drugs in development
5.1.2 Key R&D trends
5.1.2.1 Molecular targeted therapy
5.1.2.2 Immunotherapy
5.1.2.3 Biosimilars
5.2 Promising Drugs
5.2.1 Late-stage pipeline
5.2.2 Profile of disruptive drugs
5.2.2.1 Tecentriq
5.2.2.2 Binimetinib+Encorafenib+Cetuximab
5.2.2.3 MK-3475-177
5.2.2.4 Napabucasin
CHAPTER 6 COMPANY PROFILES
6.1 Amgen
6.1.1 Company overview
6.1.2 Current product portfolio
6.1.3 Product forecast sales up to 2022
6.1.4 Company - Key news flow
6.1.5 Pipeline view
6.1.6 Pipeline forecast
6.1.7 Catalysts and event calendar
6.1.8 SWOT analysis
6.2 Bayer
6.2.1 Company overview
6.2.2 Current product portfolio
6.2.3 Product forecast sales up to 2022
6.2.4 Company - Key news flow
6.2.5 Pipeline view
6.2.6 Pipeline forecast
6.2.7 Catalysts and event calendar
6.2.8 SWOT analysis
6.3 Bristol-Myers Squibb
6.3.1 Company overview
6.3.2 Current product portfolio
6.3.3 Product forecast sales up to 2022
6.3.4 Company - Key news flow
6.3.5 Pipeline view
6.3.6 Pipeline forecast
6.3.7 Catalysts and event calendar
6.3.8 SWOT analysis
6.4 Eli Lilly
6.4.1 Company overview
6.4.2 Current product portfolio
6.4.3 Product forecast sales up to 2022
6.4.4 Company - Key news flow
6.4.5 Catalysts and event calendar
6.4.6 SWOT analysis
6.5 Merck
6.5.1 Company overview
6.5.2 Current product portfolio
6.5.3 Product forecast sales up to 2022
6.5.4 Company - Key news flow
6.5.5 Pipeline view
6.5.6 Pipeline forecast
6.5.7 Catalysts and event calendar
6.5.8 SWOT analysis
6.6 Roche
6.6.1 Company overview
6.6.2 Current product portfolio
6.6.3 Product forecast sales up to 2022
6.6.4 Company - Key news flow
6.6.5 Pipeline view
6.6.6 Pipeline forecast
6.6.7 Catalysts and event calendar
6.6.8 SWOT analysis
6.7 Sanofi
6.7.1 Company overview
6.7.2 Current product portfolio
6.7.3 Product forecast sales up to 2022
6.7.4 Company - Key news flow
6.7.5 SWOT analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead
1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market formulation & validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Stages:
3.1.2 Symptoms
3.1.3 Risk Factors
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL COLORECTAL CANCER DRUGS MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Segmentation, by Drug Class
4.1.1.1 Chemotherapy
4.1.1.1.1 Antimetabolites
4.1.1.1.2 Alkylating agents
4.1.1.2 Immunotherapy
4.1.1.2.1 Biologic Response Modifiers
4.1.1.2.2 Colony-Stimulating Factors
4.1.1.2.3 Tumor Vaccines
4.1.1.2.4 Monoclonal Antibodies
4.1.2 Segmentation, by Region
4.1.2.1 U.S.
4.1.2.2 U.K.
4.1.2.3 Germany
4.1.2.4 Spain
4.1.2.5 Italy
4.1.2.6 France
4.1.2.7 Japan
4.1.3 Market size and forecast
4.1.4 Sales performance
4.1.5 Market share distribution
4.1.6 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (YTD 2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 SWOT Analysis
CHAPTER 5 COLORECTAL CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1 Pipeline Landscape
5.1.1 Drugs in development
5.1.2 Key R&D trends
5.1.2.1 Molecular targeted therapy
5.1.2.2 Immunotherapy
5.1.2.3 Biosimilars
5.2 Promising Drugs
5.2.1 Late-stage pipeline
5.2.2 Profile of disruptive drugs
5.2.2.1 Tecentriq
5.2.2.2 Binimetinib+Encorafenib+Cetuximab
5.2.2.3 MK-3475-177
5.2.2.4 Napabucasin
CHAPTER 6 COMPANY PROFILES
6.1 Amgen
6.1.1 Company overview
6.1.2 Current product portfolio
6.1.3 Product forecast sales up to 2022
6.1.4 Company - Key news flow
6.1.5 Pipeline view
6.1.6 Pipeline forecast
6.1.7 Catalysts and event calendar
6.1.8 SWOT analysis
6.2 Bayer
6.2.1 Company overview
6.2.2 Current product portfolio
6.2.3 Product forecast sales up to 2022
6.2.4 Company - Key news flow
6.2.5 Pipeline view
6.2.6 Pipeline forecast
6.2.7 Catalysts and event calendar
6.2.8 SWOT analysis
6.3 Bristol-Myers Squibb
6.3.1 Company overview
6.3.2 Current product portfolio
6.3.3 Product forecast sales up to 2022
6.3.4 Company - Key news flow
6.3.5 Pipeline view
6.3.6 Pipeline forecast
6.3.7 Catalysts and event calendar
6.3.8 SWOT analysis
6.4 Eli Lilly
6.4.1 Company overview
6.4.2 Current product portfolio
6.4.3 Product forecast sales up to 2022
6.4.4 Company - Key news flow
6.4.5 Catalysts and event calendar
6.4.6 SWOT analysis
6.5 Merck
6.5.1 Company overview
6.5.2 Current product portfolio
6.5.3 Product forecast sales up to 2022
6.5.4 Company - Key news flow
6.5.5 Pipeline view
6.5.6 Pipeline forecast
6.5.7 Catalysts and event calendar
6.5.8 SWOT analysis
6.6 Roche
6.6.1 Company overview
6.6.2 Current product portfolio
6.6.3 Product forecast sales up to 2022
6.6.4 Company - Key news flow
6.6.5 Pipeline view
6.6.6 Pipeline forecast
6.6.7 Catalysts and event calendar
6.6.8 SWOT analysis
6.7 Sanofi
6.7.1 Company overview
6.7.2 Current product portfolio
6.7.3 Product forecast sales up to 2022
6.7.4 Company - Key news flow
6.7.5 SWOT analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead
LIST OF TABLES
Table 1 Current Colorectal Cancer Prevalence Across Seven Major Markets - 2016
Table 2 Current Colorectal Cancer Incidence Across Seven Major Markets - 2016
Table 3 Forecast Colorectal Cancer Prevalence across Seven Major Markets, 2016 - 2022
Table 4 Forecast Colorectal Cancer Incidence across Seven Major Markets, 2016 - 2022
Table 5 Colorectal Cancer Drugs Market Size and Forecast (in $million)
Table 6 Geographic Sales Performance by Seven Major Markets (in $million)
Table 7 Colorectal Cancer Drugs Market by Drug Class (in $million)
Table 8 Forecast Sales of Leading Brands (in $million)
Table 9 Global Colorectal Cancer Drugs Pipeline Forecast
Table 10 Global Colorectal Cancer Drugs Pipeline Sales Forecast (in $million)
Table 11 Colorectal Cancer Drugs Sales Forecast by Company (in $million)
Table 12 Colorectal Cancer Drugs Market Share by Company (in $million)
Table 13 Colorectal Cancer Drugs Market: Patent Expiry Schedule
Table 14 Colorectal Cancer Deal Landscape YTD (2013 - 2018)
Table 15 Colorectal Cancer Drugs in Development
Table 16 Late-Stage Colorectal Cancer Pipeline
Table 17 Profile of Disruptive Drug: Tecentriq
Table 18 Profile of Disruptive Drug: Binimetinib+Encorafenib+Cetuximab
Table 19 Profile of Disruptive Drug: MK-3475-177
Table 20 Profile of Disruptive Drug: Napabucasin
Table 21 Product Portfolio: Vectibix
Table 22 Product Portfolio: Mvasi
Table 23 Vectibix Sales Forecast Through 2022
Table 24 Mvasi Sales Forecast Through 2022
Table 25 Amgen Pipeline View
Table 26 Amgen Catalysts and Event Calendar
Table 27 Product Portfolio: Stivarga
Table 28 Stivarga Sales Forecast Through 2022
Table 29 Bayer Pipeline View
Table 30 Bayer Catalysts and Event Calendar
Table 31 Product Portfolio: Opdivo
Table 32 Opdivo Sales Forecast Through 2022
Table 33 Bristol Myers Squibb Pipeline View
Table 34 Bristol Myers Squibb Catalysts and Event Calendar
Table 35 Product Portfolio: Cyramza
Table 36 Product Portfolio: Erbitux
Table 37 Cyramza Sales Forecast Through 2022
Table 38 Erbitux Sales Forecast Through 2022
Table 39 Eli Lilly Catalysts and Event Calendar
Table 40 Product Portfolio: Keytruda
Table 41 Keytruda Sales Forecast Through 2022
Table 42 Merck Pipeline View
Table 43 Merck Catalysts and Event Calendar
Table 44 Product Portfolio: Avastin
Table 45 Product Portfolio: Xeloda
Table 46 Avastin Sales Forecast Through 2022
Table 47 Xeloda Sales Forecast Through 2022
Table 48 Roche Pipeline View
Table 49 Roche Catalysts and Event Calendar
Table 50 Product Portfolio: Zaltrap
Table 51 Product Portfolio: Eloxatin
Table 52 Zaltrap Sales Forecast Through 2022
Table 53 Eloxatin Sales Forecast Through 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Stages of colorectal cancer
Fig. 8 Current prevalence across seven major markets - 2016
Fig. 9 Current incidence across seven major markets - 2016
Fig. 10 Geographic sales performance by seven major markets 2016
Fig. 11 Colorectal cancer drugs market by drug class
Fig. 12 Colorectal cancer drugs market share by company 2016 - 2022
Fig. 13 Market trends & outlook
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 SWOT analysis (Colorectal cancer drugs market)
Fig. 17 SWOT analysis (Amgen)
Fig. 18 SWOT analysis (Bayer)
Fig. 19 SWOT analysis (Bristol Myers Squibb)
Fig. 20 SWOT analysis (Eli Lilly)
Fig. 21 SWOT analysis (Merck)
Fig. 22 SWOT analysis (Roche)
Fig. 23 SWOT analysis (Sanofi)
Table 1 Current Colorectal Cancer Prevalence Across Seven Major Markets - 2016
Table 2 Current Colorectal Cancer Incidence Across Seven Major Markets - 2016
Table 3 Forecast Colorectal Cancer Prevalence across Seven Major Markets, 2016 - 2022
Table 4 Forecast Colorectal Cancer Incidence across Seven Major Markets, 2016 - 2022
Table 5 Colorectal Cancer Drugs Market Size and Forecast (in $million)
Table 6 Geographic Sales Performance by Seven Major Markets (in $million)
Table 7 Colorectal Cancer Drugs Market by Drug Class (in $million)
Table 8 Forecast Sales of Leading Brands (in $million)
Table 9 Global Colorectal Cancer Drugs Pipeline Forecast
Table 10 Global Colorectal Cancer Drugs Pipeline Sales Forecast (in $million)
Table 11 Colorectal Cancer Drugs Sales Forecast by Company (in $million)
Table 12 Colorectal Cancer Drugs Market Share by Company (in $million)
Table 13 Colorectal Cancer Drugs Market: Patent Expiry Schedule
Table 14 Colorectal Cancer Deal Landscape YTD (2013 - 2018)
Table 15 Colorectal Cancer Drugs in Development
Table 16 Late-Stage Colorectal Cancer Pipeline
Table 17 Profile of Disruptive Drug: Tecentriq
Table 18 Profile of Disruptive Drug: Binimetinib+Encorafenib+Cetuximab
Table 19 Profile of Disruptive Drug: MK-3475-177
Table 20 Profile of Disruptive Drug: Napabucasin
Table 21 Product Portfolio: Vectibix
Table 22 Product Portfolio: Mvasi
Table 23 Vectibix Sales Forecast Through 2022
Table 24 Mvasi Sales Forecast Through 2022
Table 25 Amgen Pipeline View
Table 26 Amgen Catalysts and Event Calendar
Table 27 Product Portfolio: Stivarga
Table 28 Stivarga Sales Forecast Through 2022
Table 29 Bayer Pipeline View
Table 30 Bayer Catalysts and Event Calendar
Table 31 Product Portfolio: Opdivo
Table 32 Opdivo Sales Forecast Through 2022
Table 33 Bristol Myers Squibb Pipeline View
Table 34 Bristol Myers Squibb Catalysts and Event Calendar
Table 35 Product Portfolio: Cyramza
Table 36 Product Portfolio: Erbitux
Table 37 Cyramza Sales Forecast Through 2022
Table 38 Erbitux Sales Forecast Through 2022
Table 39 Eli Lilly Catalysts and Event Calendar
Table 40 Product Portfolio: Keytruda
Table 41 Keytruda Sales Forecast Through 2022
Table 42 Merck Pipeline View
Table 43 Merck Catalysts and Event Calendar
Table 44 Product Portfolio: Avastin
Table 45 Product Portfolio: Xeloda
Table 46 Avastin Sales Forecast Through 2022
Table 47 Xeloda Sales Forecast Through 2022
Table 48 Roche Pipeline View
Table 49 Roche Catalysts and Event Calendar
Table 50 Product Portfolio: Zaltrap
Table 51 Product Portfolio: Eloxatin
Table 52 Zaltrap Sales Forecast Through 2022
Table 53 Eloxatin Sales Forecast Through 2022LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Stages of colorectal cancer
Fig. 8 Current prevalence across seven major markets - 2016
Fig. 9 Current incidence across seven major markets - 2016
Fig. 10 Geographic sales performance by seven major markets 2016
Fig. 11 Colorectal cancer drugs market by drug class
Fig. 12 Colorectal cancer drugs market share by company 2016 - 2022
Fig. 13 Market trends & outlook
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 SWOT analysis (Colorectal cancer drugs market)
Fig. 17 SWOT analysis (Amgen)
Fig. 18 SWOT analysis (Bayer)
Fig. 19 SWOT analysis (Bristol Myers Squibb)
Fig. 20 SWOT analysis (Eli Lilly)
Fig. 21 SWOT analysis (Merck)
Fig. 22 SWOT analysis (Roche)
Fig. 23 SWOT analysis (Sanofi)
